Title: Drug Safety and Pharmacovigilance Protocol

Document ID: PHARMA-PV-2024-001

Adverse Event Monitoring:
- Continuous monitoring of all approved products
- Literature surveillance weekly
- Social media monitoring daily
- Patient support program tracking

Signal Detection:
- Statistical signal detection quarterly
- Medical review of all serious events
- Aggregate analysis monthly
- Risk-benefit assessment ongoing

Quality Management:
- GVP (Good Vigilance Practice) compliance
- Standard operating procedures maintained
- Training program for all staff
- Quality metrics tracked monthly

Regulatory Reporting:
- MedWatch submissions per FDA requirements
- Periodic safety update reports
- Risk evaluation and mitigation strategies
- Regulatory intelligence monitoring
